Neurofibrosarcoma
A malignant tumor that arises from small cutaneous nerves, is locally aggressive, and has a potential for metastasis. Characteristic histopathologic features include proliferating atypical spindle cells with slender wavy and pointed nuclei, hypocellular areas, and areas featuring organized whorls of fibroblastic proliferation. The most common primary sites are the extremities, retroperitoneum, and trunk. These tumors tend to present in childhood, often in association with NEUROFIBROMATOSIS 1. (From DeVita et al., Cancer: Principles & Practice of Oncology, 5th ed, p1662; Mayo Clin Proc 1990 Feb;65(2):164-72)
Drugs by status
Phase 3 trials (4)
Phase 2 trials (19)
Organizations
Organization Involved with Phase 3 Indications (2)
Organization Involved with Phase 2 Indications (26)
- Bristol-Myers Squibb
- AstraZeneca
- Merck
- Genentech
- Plexxikon
- Bayer
- Synta Pharmaceuticals Corp.
- Cornell University
- Harvard University
- Northwestern University
- Oregon Health and Science University
- Osaka University
- Sarcoma Alliance for Research through Collaboration
- Southwest Oncology Group
- University of Michigan
- Wake Forest University
- Columbia University
- University of California, Los Angeles
- University of Utah
- Department of Defense
- University of Texas at Houston
- Maria Sklodowska Curie Children's Hospital
- Washington University in St. Louis
- Children's National Medical Center
- National Comprehensive Cancer Network
- The University of Texas, Dallas
Organization Involved with Phase 1 Indications (7)
Organization Involved with Other Experimental Indications (2)